#Taiwan #Taipei #HanchorBio #HCB101 #CD47-SIRPα

HanchorBio's Innovative CD47-SIRPα Therapy HCB101

HanchorBio Inc., a pioneering biotechnology company based in Taipei, Shanghai, and the San Francisco Bay Area, has achieved a significant milestone with the publication of its research on HCB101 in the esteemed Journal of Hematology & Oncology. The published manuscript focuses on the promising results of HCB101, which is engineered to target the CD47-SIRPα pathway, showing high safety and efficacy in both hematological malignancies and solid tumors.

Overview of HCB101

HCB101 is characterized as a 3.5th-generation SIRPα-Fc fusion protein, and it has been developed using HanchorBio's proprietary FBDB™ platform. This innovative therapy optimally balances efficacy with a minimal risk of hematologic toxicity, which is a common concern associated with previous CD47-targeted therapies. HCB101 demonstrates enhanced antibody-dependent cellular phagocytosis (ADCP) and effectively bridges innate and adaptive immune responses, making it a potential game-changer in cancer treatment.

The study outlines the rationale behind the engineering of HCB101, emphasizing its ability to stimulate macrophage-mediated phagocytosis while minimizing interaction with red blood cells. This targeted mechanism has resulted in substantial activity across over 80 xenograft and patient-derived xenograft (PDX) models, showcasing a safety profile distinct from earlier generations of CD47-focused therapies.

Clinical Insights and Results

One of the most notable findings reported in the publication includes a nearly 90% partial response rate in patients with second-line gastric cancer when used in combination with established treatment methods. These promising results occurred at specific dosages of HCB101, indicating its potential effectiveness as a backbone treatment in oncology. In clinical trials, the monotherapy phase of HCB101 has escalated to 30 mg/kg with no reported dose-limiting toxicities, reinforcing its strong therapeutic window.

Published Data Reflecting Strong Potential

Dr. Scott Liu, CEO of HanchorBio, expressed the significance of this publication, stating, "The acceptance of our research in the Journal of Hematology & Oncology validates the scientific rigor and innovative approaches behind HCB101. Our efforts are now translating into promising clinical outcomes, advancing our potential to revolutionize standard care in oncology and autoimmune disorders alike."

The clinical data released indicates two confirmed partial responses in cases of head and neck squamous cell carcinoma and marginal zone lymphoma, alongside sustained disease control for over 40 weeks in a patient with platinum-resistant ovarian cancer.

Future Directions

HCB101 is currently undergoing extensive clinical evaluation in multinational Phase 1/1b/2a trials, focusing on both monotherapy and combination regimens. The combination study, involving HCB101, ramucirumab, and paclitaxel for second-line gastric cancer treatment, has also produced notable efficacy signals, reinforcing HCB101’s potential to significantly improve patient outcomes in challenging cancer cases. The drug's differential mechanism of action and favorable safety profile position it well for addressing unmet needs in both oncology and autoimmune disease treatment areas.

In summary, HanchorBio’s HCB101 stands at the forefront of a new generation of immunotherapy, showing exceptional promise in preclinical and clinical settings. The findings published reinforce the hope for broader future applications beyond cancer immunotherapy, particularly in the realm of autoimmune therapies.

For more information on HanchorBio and their innovative therapeutic approaches, please visit their official website.